Development of Submacular Hemorrhage in Neovascular Age-related Macular Degeneration: Influence on Visual Prognosis in a Clinical Setting
3
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to evaluate changes in visual acuity before and after the development of submacular hemorrhage secondary to neovascular age-related macular degeneration (AMD) and to compare the visual outcomes between patients with and without hemorrhage. Methods: This retrospective observational study included 124 patients with neovascular AMD. Patients who developed a submacular hemorrhage involving the fovea were included in the hemorrhage group (n = 55). Patients with no sign of submacular hemorrhage during the follow-up period were included in the no-hemorrhage group (n = 69). Visual outcomes were compared between the two groups. Results: The logarithm of the minimal angle of resolution best-corrected visual acuity (BCVA) before the development of submacular hemorrhage, once the hemorrhage had developed, and 6 months after the development of hemorrhage was 0.59 ± 0.45, 1.24 ± 0.57, and 0.99 ± 0.64, respectively. BCVA was significantly worse 6 months after the hemorrhage compared to before the hemorrhage (p < 0.001). The BCVA before the development of hemorrhage (measured at a mean of 12.9 months after diagnosis) was comparable to that of the no-hemorrhage group (mean, 0.58 ± 0.37 at a mean of 12.4 months). However, the BCVA 6 months after identification of hemorrhage (mean, 21.5 months) was significantly worse in the hemorrhage group than in the no-hemorrhage group (mean, 0.73 ± 0.44 at mean 21.2 months) (p = 0.018). Conclusions: Visual acuity was significantly worse after hemorrhage than before hemorrhage, even after treatment. In addition, patients with submacular hemorrhage had markedly worse visual outcomes than patients without hemorrhage. This result suggests that the development of hemorrhage during the treatment course of neovascular AMD has a devastating effect on visual prognosis.
Abstract
Purpose: This study aimed to evaluate changes in visual acuity before and after the development of submacular hemorrhage secondary to neovascular age-related macular degeneration (AMD) and to compare the visual outcomes between patients with and without hemorrhage. Methods: This retrospective observational study included 124 patients with neovascular AMD. Patients who developed a submacular hemorrhage involving the fovea were included in the hemorrhage group (n = 55). Patients with no sign of submacular hemorrhage during the follow-up period were included in the no-hemorrhage group (n = 69). Visual outcomes were compared between the two groups. Results: The logarithm of the minimal angle of resolution best-corrected visual acuity (BCVA) before the development of submacular hemorrhage, once the hemorrhage had developed, and 6 months after the development of hemorrhage was 0.59 ± 0.45, 1.24 ± 0.57, and 0.99 ± 0.64, respectively. BCVA was significantly worse 6 months after the hemorrhage compared to before the hemorrhage (p < 0.001). The BCVA before the development of hemorrhage (measured at a mean of 12.9 months after diagnosis) was comparable to that of the no-hemorrhage group (mean, 0.58 ± 0.37 at a mean of 12.4 months). However, the BCVA 6 months after identification of hemorrhage (mean, 21.5 months) was significantly worse in the hemorrhage group than in the no-hemorrhage group (mean, 0.73 ± 0.44 at mean 21.2 months) (p = 0.018). Conclusions: Visual acuity was significantly worse after hemorrhage than before hemorrhage, even after treatment. In addition, patients with submacular hemorrhage had markedly worse visual outcomes than patients without hemorrhage. This result suggests that the development of hemorrhage during the treatment course of neovascular AMD has a devastating effect on visual prognosis.
참고문헌 (18)
- Avery RL, "Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration", Retina, 16, pp.183~189 (1996)[DOI]
- Bressler NM, "Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13", Ophthalmology, 111, pp.1993~2006 (2004)[DOI]
- Scupola A, "Natural history of macular subretinal hemorrhage in age-related macular degeneration", Ophthalmologica, 213, pp.97~102 (1999)[DOI]
- Hassan AS, "Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement", Ophthalmology, 106, pp.1900~1906 (1999)[DOI]
- Haupert CL, "Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration", Am J Ophthalmol, 131, pp.208~215 (2001)[DOI]
- Kamei M, "Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid", Am J Ophthalmol, 121, pp.267~275 (1996)[DOI]
- Chang M A, "Prospective oneyear study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration", Retina, 30, pp.1171~1176 (2010)[DOI]
- Kim JH, "Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization", Ophthalmology, 121, pp.926~935 (2014)[DOI]
- Shienbaum G, "Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy", Am J Ophthalmol, 155, pp.1009~1013 (2013)[DOI]
- Stifter E, "Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage", Am J Ophthalmol, 144, pp.886~892 (2007)[DOI]
- Altaweel MM, "O utcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)", Ophthalmology, 122, pp.391~398 (2015)[DOI]
- Shin JY, "Anti-vascular endothelial growth factor with or without pneumatic displacement for submacular hemorrhage", Am J Ophthalmol, 159, pp.904~914 (2015)[DOI]
- 김건해, "Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor", Korean Journal of Ophthalmology, 29(5), pp.315~324 (2015), 대한안과학회
- Kyung-Hoon Shin, "The Efficacy of Intravitreal Aflibercept in Submacular Hemorrhage Secondary to Wet Age-related Macular Degeneration", Korean Journal of Ophthalmology, 30(5), pp.369~376 (2016), 대한안과학회
- Cho JH, "Incidence rate of massive submacular hemorrhage and its risk factors in polypoidal choroidal vasculopathy", Am J Ophthalmol, 169, pp.79~88 (2016)[DOI]
- Kim KM, "Long-term outcomes in patients with neovascular age-related macular degeneration who maintain dry macula after three monthly ranibizumab injections", Semin Ophthalmol, 33, pp.371~376 (2018)[DOI]
- Kuroda Y, "Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study", Ophthalmology, 122, pp.2303~2310 (2015)[DOI]
- Hesgaard HB, "Failure to detect an effect of pneumatic displacement in the management of submacular haemorrhage secondary to age-related macular degeneration: a retrospective case series", Acta Ophthalmol, 90, pp.e498~e500 (2012)[DOI]